Literature DB >> 8207003

Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease.

L Menéndez-Arias1, I T Weber, J Soss, R W Harrison, D Gotte, S Oroszlan.   

Abstract

The substrate specificity of the Moloney murine leukemia virus protease (Mo-MuLV PR) was analyzed by using the oligopeptide substrate Val-Ser-Gln-Asn-Tyr decreases Pro-Ile-Val-Gln-NH2 and a series of analogs containing single amino acid substitutions in the P4-P3' positions. Mo-MuLV PR appears to act similarly to the human immunodeficiency virus (HIV) PRs, except for peptides having substitutions at P4 and P2 positions. Mo-MuLV PR shows a strong preference for the analogs having hydrophobic residues, such as Val or Ile at P4, and Ile and Leu at P2, in contrast to HIV-1 and HIV-2 PRs, which prefer smaller or more polar residues at both positions. We built a molecular model of Mo-MuLV PR on the basis of the crystal structure of the related HIV PR. Although the overall structure of Mo-MuLV PR is predicted to be close to that of HIV-1 PR, almost all of the residues forming the subsites are different. The increased hydrophobicity due to the Pro12 insertion and the presence of more aromatic residues in the S4 subsite of Mo-MuLV PR compared to HIV-1 and HIV-2 PRs can be correlated with the observed differences using P4-substituted analogs of VSQNYPIVQ. The preference of Mo-MuLV PR for larger hydrophobic residues at the P2 position can be correlated with the larger size of its S2 subsite, due in part to the presence of Val39, Ala57, and His84 in Mo-MuLV PR, instead of Ile32, Ile50, and Met76, respectively, as occurs in HIV-2 PR.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207003

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Inhibition of XMRV and HIV-1 proteases by pepstatin A and acetyl-pepstatin.

Authors:  Krisztina Matúz; János Mótyán; Mi Li; Alexander Wlodawer; József Tőzsér
Journal:  FEBS J       Date:  2012-08-17       Impact factor: 5.542

2.  Comprehensive mutational analysis of the Moloney murine leukemia virus envelope protein.

Authors:  S M Rothenberg; M N Olsen; L C Laurent; R A Crowley; P O Brown
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.

Authors:  Péter Bagossi; Tamás Sperka; Anita Fehér; János Kádas; Gábor Zahuczky; Gabriella Miklóssy; Péter Boross; József Tözsér
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Efficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells.

Authors:  S K Powell; M Artlip; M Kaloss; S Brazinski; R Lyons; G J McGarrity; E Otto
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

5.  Specificity of Retroviral Proteinases Based on Substrates Containing Tyrosine and Proline at the Site of Cleavage.

Authors:  József Tözsér
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

6.  Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.

Authors:  Helga Eizert; Pálma Bander; Péter Bagossi; Tamás Sperka; Gabriella Miklóssy; Péter Boross; Irene T Weber; József Tözsér
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

7.  The eukaryotic translation initiation factor 4GI is cleaved by different retroviral proteases.

Authors:  Enrique Alvarez; Luis Menéndez-Arias; Luis Carrasco
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

8.  Comparative studies on retroviral proteases: substrate specificity.

Authors:  József Tözsér
Journal:  Viruses       Date:  2010-01-14       Impact factor: 5.818

Review 9.  HIV Protease: Historical Perspective and Current Research.

Authors:  Irene T Weber; Yuan-Fang Wang; Robert W Harrison
Journal:  Viruses       Date:  2021-05-06       Impact factor: 5.048

10.  Gag-Pol processing during HIV-1 virion maturation: a systems biology approach.

Authors:  Balázs Könnyű; S Kashif Sadiq; Tamás Turányi; Rita Hírmondó; Barbara Müller; Hans-Georg Kräusslich; Peter V Coveney; Viktor Müller
Journal:  PLoS Comput Biol       Date:  2013-06-06       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.